Last reviewed 2026-04-20 · How we verify

AFURESERTIB

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhoea
• Fatigue
• Cough
• Neutropenia
• Vomiting
• Chest discomfort
• Upper respiratory tract infection
• Urinary tract infection
• Decreased appetite
• Epistaxis
• Nasal congestion
• Pruritus

Key clinical trials

• Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 (PHASE1, PHASE2)
• Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer (PHASE3)
• Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PHASE2)
• PhI to Solid Tumors and PhII to Locally Advanced or mTNBC (PHASE1)
• Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (PHASE1, PHASE2)
• Human Mass Balance and Biotransformation Study of [14C]Afuresertib (PHASE1)
• Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients (PHASE1)
• Continuation Study of the Oral AKT Inhibitor GSK2110183 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.